Retension Pharmaceuticals

General Information
Business:

(Incorporated in Delaware)

We are a clinical stage biotech developing just one drug candidate, RTN-001, a daily pill for uncontrolled and resistant hypertension. We are evaluating RTN-001 in a Phase 2b trial that began in October 2025. We expect initial data in the first half of 2027.

Note: Net loss is for the 12 months that ended on June 30, 2026. The company has no product revenue, according to the prospectus. 

(Note: Retension Pharmaceuticals priced its small IPO at $12.00 – the mid-point of its range – and upsized the IPO at pricing to 3.75 million shares – up from 3.3 million shares in the prospectus – to raise $45 million on Thursday night, Oct. 8, 2026. Background: Retension Pharmaceuticals filed its S-1/A on Oct. 5, 2026, and disclosed the terms for its IPO: 3.3 million shares at a price range of $11.00 to $13.00 to raise $39.6 million, if priced at the $12.00 mid-point of its range. Background: Retension Pharmaceuticals filed its S-1 for its IPO on Sept. 18, 2026, without disclosing the terms. Estimated proceeds were $60 million.)

Industry: Pharmaceuticals
Employees:
Founded: 2023
Contact Information
Address 1104 West Broad Street #1029 Falls Church, Virginia 22046
Phone Number (703) 940-9761
Web Address http://www.retensionpharmaceuticals.com/
View Prospectus: Retension Pharmaceuticals
Financial Information
Market Cap $99.96mil
Revenues $0.0 mil (last 12 months)
Net Income $-11.94 mil (last 12 months)
IPO Profile
Symbol RTSN
Exchange NASDAQ
Shares (millions): 3.8
Price range $12.00 - $12.00
Est. $ Volume $45.0 mil
Manager / Joint Managers Leerink Partners/Guggenheim Securities/Oppenheimer & Co./Titan Partners
CO-Managers
Expected To Trade: 10/9/2026
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change